Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling

Abstract

Histone demethylase JMJD2D can promote gene expression by specifically demethylating H3K9me2/3. The role of JMJD2D in colitis and colitis-associated colorectal cancer (CRC) progression remains unclear. Here, we show that colonic JMJD2D is induced by TNFα during dextran sulfate sodium-induced colitis. JMJD2D-deficient mice exhibit more severe colon damage and defective colon regeneration due to impaired Hedgehog signaling activation after colitis. JMJD2D knockdown in CRC cells suppresses Hedgehog signaling, resulting in reduced CRC growth and metastasis. Mechanistically, JMJD2D promotes Hedgehog target gene expression through interacting with Gli2 to reduce H3K9me3 levels at the promoter. Clinically, JMJD2D expression is upregulated and positively correlated with Gli2 expression in human inflammatory bowel disease specimens and CRC specimens. The JMJD2D inhibitor 5-c-8HQ or aspirin synergizes with Hedgehog inhibitor vismodegib to inhibit CRC cell proliferation and tumorigenesis. Collectively, our findings unveil an essential role of JMJD2D in activating the processes of colonic protection, regeneration, and tumorigenesis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: JMJD2D expression is induced by TNFα and JMJD2D−/− mice are more sensitive to DSS-induced colitis compared with wild-type mice.
Fig. 2: JMJD2D protects colonic epithelial cells from DSS-induced apoptosis and promotes colonic epithelial cell proliferation by activating Hedgehog signaling.
Fig. 3: JMJD2D promotes CRC cell proliferation, xenograft growth, migration, invasion, and lung metastasis by activating Hedgehog signaling.
Fig. 4: JMJD2D promotes Hedgehog target gene transcription through interacting with Gli2 to reduce H3K9me3 levels at the promoter.
Fig. 5: JMJD2D and Gli2 are frequently overexpressed in human IBD and CRC specimens.
Fig. 6: 5-c-8HQ synergizes with vismodegib to reduce Hedgehog target gene expression and to inhibit CRC cell proliferation and tumorigenesis.
Fig. 7: Aspirin synergizes with Hedgehog inhibitor vismodegib to reduce Hedgehog target gene expression and to inhibit HCT116 cell proliferation and tumorigenesis.
Fig. 8: Schematic model for the mechanism by which JMJD2D activates the Hedgehog signaling to promote colonic protection, regeneration, and tumorigenesis during colitis.

References

  1. 1.

    Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101–14.

  2. 2.

    Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807–16.

  3. 3.

    Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–60.

  4. 4.

    Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009;6:297–305.

  5. 5.

    Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295–309.

  6. 6.

    Fattahi S, Pilehchian Langroudi M, Akhavan-Niaki H. Hedgehog signaling pathway: epigenetic regulation and role in disease and cancer development. J Cell Physiol. 2018;233:5726–35.

  7. 7.

    Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell. 2008;15:801–12.

  8. 8.

    Buller NV, Rosekrans SL, Westerlund J, van den Brink GR. Hedgehog signaling and maintenance of homeostasis in the intestinal epithelium. Physiology. 2012;27:148–55.

  9. 9.

    Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer. 2006;42:437–45.

  10. 10.

    Dai P, Akimaru H, Tanaka Y, Maekawa T, Nakafuku M, Ishii S. Sonic hedgehog-induced activation of the Gli1 promoter is mediated by GLI3. J Biol Chem. 1999;274:8143–52.

  11. 11.

    Ikram MS, Neill GW, Regl G, Eichberger T, Frischauf AM, Aberger F, et al. GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Investig Dermatol. 2004;122:1503–9.

  12. 12.

    Lees CW, Zacharias WJ, Tremelling M, Noble CL, Nimmo ER, Tenesa A, et al. Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways. PLoS Med. 2008;5:e239.

  13. 13.

    Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, et al. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. Embo Mol Med. 2009;1:338–51.

  14. 14.

    Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332.

  15. 15.

    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9.

  16. 16.

    Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013;19:258–67.

  17. 17.

    Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol. 2015;33:4284–92.

  18. 18.

    Accari SL, Fisher PR. Emerging roles of JmjC domain-containing proteins. Int Rev Cell Mol Biol. 2015;319:165–220.

  19. 19.

    Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 2013;73:2936–42.

  20. 20.

    Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell. 2006;125:467–81.

  21. 21.

    Peng K, Kou L, Yu L, Bai C, Li M, Mo P, et al. Histone demethylase JMJD2D interacts with beta-catenin to induce transcription and activate colorectal cancer cell proliferation and tumor growth in mice. Gastroenterology. 2019;156:1112–26.

  22. 22.

    Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–9.

  23. 23.

    Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90.

  24. 24.

    Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956–9.

  25. 25.

    Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77–80.

  26. 26.

    Xiao YT, Yan WH, Cao Y, Yan JK, Cai W. Neutralization of IL-6 and TNF-alpha ameliorates intestinal permeability in DSS-induced colitis. Cytokine. 2016;83:189–92.

  27. 27.

    Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, et al. Anti TNF-alpha therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol. 2017;13:223–33.

  28. 28.

    Naito Y, Takagi T, Handa O, Ishikawa T, Nakagawa S, Yamaguchi T, et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol. 2003;18:560–9.

  29. 29.

    Xu Y, Hunt NH, Bao S. The correlation between proinflammatory cytokines, MAdCAM-1 and cellular infiltration in the inflamed colon from TNF-alpha gene knockout mice. Immunol Cell Biol. 2007;85:633–9.

  30. 30.

    Wang Y, Han G, Chen Y, Wang K, Liu G, Wang R, et al. Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response. Lab Investig. 2013;93:1024–35.

  31. 31.

    Sipos F, Zagoni T, Molnar B, Tulassay Z. Changes in the proliferation and apoptosis of colonic epithelial cells in correlation with histologic activity of ulcerative colitis. Orv Hetil. 2002;143:2485–8.

  32. 32.

    Mizushima T, Arakawa S, Sanada Y, Yoshino I, Miyazaki D, Urushima H, et al. Inhibition of epithelial cell death by Bcl-2 improved chronic colitis in IL-10 KO mice. Am J Pathol. 2013;183:1936–44.

  33. 33.

    Regl G, Kasper M, Schnidar H, Eichberger T, Neill GW, Philpott MP, et al. Activation of the BCL2 promoter in response to hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res. 2004;64:7724–31.

  34. 34.

    Geng H, Bu HF, Liu F, Wu L, Pfeifer K, Chou PM, et al. In inflamed intestinal tissues and epithelial cells, interleukin 22 signaling increases expression of H19 long noncoding RNA, which promotes mucosal regeneration. Gastroenterology. 2018;155:144–55.

  35. 35.

    Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell. 2013;23:93–106.

  36. 36.

    Elinav E, Nowarski R, Thaiss CA, Hu B, Jin CC, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.

  37. 37.

    Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–96.

  38. 38.

    Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, Nemoto Y, et al. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G850–9.

  39. 39.

    Rominger CM, Bee WL, Copeland RA, Davenport EA, Gilmartin A, Gontarek R, et al. Evidence for allosteric interactions of antagonist binding to the smoothened receptor. J Pharm Exp Ther. 2009;329:995–1005.

  40. 40.

    Ranganathan P, Jayakumar C, Manicassamy S, Ramesh G. CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation. Am J Physiol Ren Physiol. 2013;305:F1422–7.

  41. 41.

    Zhao B, Qi Z, Li Y, Wang C, Fu W, Chen YG. The non-muscle-myosin-II heavy chain Myh9 mediates colitis-induced epithelium injury by restricting Lgr5+ stem cells. Nat Commun. 2015;6:7166.

  42. 42.

    Das S, Rachagani S, Sheinin Y, Smith LM, Gurumurthy CB, Roy HK, et al. Mice deficient in Muc4 are resistant to experimental colitis and colitis-associated colorectal cancer. Oncogene. 2016;35:2645–54.

  43. 43.

    Chen W, Zhuo M, Lu X, Xia X, Zhao Y, Huang Z, et al. SRC-3 protects intestine from DSS-induced colitis by inhibiting inflammation and promoting goblet cell differentiation through enhancement of KLF4 expression. Int J Biol Sci. 2018;14:2051–64.

  44. 44.

    Tong ZW, Li M, Wang W, Mo PL, Yu L, Liu K, et al. Steroid receptor coactivator 1 promotes human hepatocellular carcinoma progression by enhancing Wnt/beta-catenin signaling. J Biol Chem. 2015;290:18596–608.

Download references

Acknowledgements

We thank Shiwen Luo (Nanchang University) for providing Gli2 expression plasmid and Hedgehog signaling reporter 8 × GBS, Chenglin Bian for TCGA data analysis, and Lei Huang for technical support. This study was supported by grants from the National Natural Science Foundation of China (no. 81970485 to CY), the National Natural Science Foundation of China (no. 81772942 to CY), the National Basic Research Program of China (973 Program, no. 2015CB553800 to CY), the National Natural Science Foundation of China (no. 81901597 to WC), the National Science and Technology Major Project of China (2017ZX10203206 to WL), the Scientific Research Foundation for Advanced Talents, Xiang’an Hospital of Xiamen University (no. PM20180917008 to WL), the Natural Science Foundation of Fujian Province (2017J01268 to XQ), and the National Health and Family Planning Commission’s Scientific Research Foundation-Health and Education cooperation foundation (WKJ2016-2-17 to XQ).

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Xingfeng Qiu or Wengang Li or Chundong Yu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All Animal experiments were conducted under protocols approved by the Laboratory Animal Center of Xiamen University. For experiments using human specimens, all specimens were anonymously coded in accordance with the Declaration of Helsinki. The study protocol that conformed to the ethical guidelines was approved by the Institute Research Ethics Committee at Xiamen University.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhuo, M., Chen, W., Shang, S. et al. Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling. Oncogene 39, 3336–3353 (2020). https://doi.org/10.1038/s41388-020-1219-2

Download citation